ARTICLE | Clinical News

Alpha-1 antitrypsin: Phase II

February 14, 2000 8:00 AM UTC

In a 12-patient trial in the U.K. and Ireland, single intravenous doses of 60 mg/kg or 120 mg/kg of transgenic AAT produced a similar plasma half-life to single doses of Bayer's Prolastin plasma-derived human AAT. However, transgenic AAT had a lower circulating level compared to Prolastin. The transgenic AAT was well tolerated. ...